Frontiers in Oncology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志未来预警的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了，催了几次都说会催诚信团队，但至今都卡在技术审查这步，有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肺癌 经验分享：非常快！ 27 Sep 2023 Article accepted for publication. Submitting Author re-submitted manuscript. 25 Sep 2023 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 2 is finalized. Review of Reviewer 1 is finalized. 13 Sep 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人，且这个审稿人审稿结束了，同意出版。编辑说还要邀请审稿人呢，一个审稿人不行，已经过去半个月了，还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向：头颈肿瘤;影像;Oncology 经验分享：请问我的一个个案，自我感觉头颈肿瘤和肿瘤影像两部分都可以投，我投了头颈肿瘤，但是现在已经快EA一个月了，我上面至今都没有编辑的名字（没分到编辑），我也写信推荐了（他说我可以推荐一个可能的编辑）。请问各位大佬们，如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试，不行就换杂志了，伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0 经验分享：一个月了状态还停留在Initial Validation阶段，催稿也未回复，有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向：非小细胞肺癌;临床;肿瘤免疫 经验分享：FII被拒了，能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]

2023-11-21 清清欢来自江西省

偏重的研究方向：肿瘤免疫
经验分享：这个杂志未来预警的可能性大吗？

7 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志未来预警的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了，催了几次都说会催诚信团队，但至今都卡在技术审查这步，有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肺癌 经验分享：非常快！ 27 Sep 2023 Article accepted for publication. Submitting Author re-submitted manuscript. 25 Sep 2023 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 2 is finalized. Review of Reviewer 1 is finalized. 13 Sep 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人，且这个审稿人审稿结束了，同意出版。编辑说还要邀请审稿人呢，一个审稿人不行，已经过去半个月了，还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向：头颈肿瘤;影像;Oncology 经验分享：请问我的一个个案，自我感觉头颈肿瘤和肿瘤影像两部分都可以投，我投了头颈肿瘤，但是现在已经快EA一个月了，我上面至今都没有编辑的名字（没分到编辑），我也写信推荐了（他说我可以推荐一个可能的编辑）。请问各位大佬们，如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试，不行就换杂志了，伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0 经验分享：一个月了状态还停留在Initial Validation阶段，催稿也未回复，有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向：非小细胞肺癌;临床;肿瘤免疫 经验分享：FII被拒了，能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]

2023-10-30 小鹏友来自重庆

审稿速度:3.0 | 投稿命中率:95.0
偏重的研究方向：肿瘤
经验分享：非常水……😌😌😌😌

18 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志未来预警的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了，催了几次都说会催诚信团队，但至今都卡在技术审查这步，有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肺癌 经验分享：非常快！ 27 Sep 2023 Article accepted for publication. Submitting Author re-submitted manuscript. 25 Sep 2023 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 2 is finalized. Review of Reviewer 1 is finalized. 13 Sep 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人，且这个审稿人审稿结束了，同意出版。编辑说还要邀请审稿人呢，一个审稿人不行，已经过去半个月了，还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向：头颈肿瘤;影像;Oncology 经验分享：请问我的一个个案，自我感觉头颈肿瘤和肿瘤影像两部分都可以投，我投了头颈肿瘤，但是现在已经快EA一个月了，我上面至今都没有编辑的名字（没分到编辑），我也写信推荐了（他说我可以推荐一个可能的编辑）。请问各位大佬们，如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试，不行就换杂志了，伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0 经验分享：一个月了状态还停留在Initial Validation阶段，催稿也未回复，有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向：非小细胞肺癌;临床;肿瘤免疫 经验分享：FII被拒了，能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]

2023-10-04 ms1000000556586108 来自湖南省

技术审查一个多月了，催了几次都说会催诚信团队，但至今都卡在技术审查这步，有人遇到过同样情况吗😮‍💨

24 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志未来预警的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了，催了几次都说会催诚信团队，但至今都卡在技术审查这步，有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肺癌 经验分享：非常快！ 27 Sep 2023 Article accepted for publication. Submitting Author re-submitted manuscript. 25 Sep 2023 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 2 is finalized. Review of Reviewer 1 is finalized. 13 Sep 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人，且这个审稿人审稿结束了，同意出版。编辑说还要邀请审稿人呢，一个审稿人不行，已经过去半个月了，还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向：头颈肿瘤;影像;Oncology 经验分享：请问我的一个个案，自我感觉头颈肿瘤和肿瘤影像两部分都可以投，我投了头颈肿瘤，但是现在已经快EA一个月了，我上面至今都没有编辑的名字（没分到编辑），我也写信推荐了（他说我可以推荐一个可能的编辑）。请问各位大佬们，如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试，不行就换杂志了，伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0 经验分享：一个月了状态还停留在Initial Validation阶段，催稿也未回复，有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向：非小细胞肺癌;临床;肿瘤免疫 经验分享：FII被拒了，能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]

2023-11-10 ms4000000828277451 来自山东省

审稿速度:1.0 | 投稿命中率:95.0
偏重的研究方向：肺癌
经验分享：非常快！
27 Sep 2023
Article accepted for publication.
Submitting Author re-submitted manuscript.
25 Sep 2023
Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript.
Review of Reviewer 2 is finalized.
Review of Reviewer 1 is finalized.
13 Sep 2023
Submitting Author submitted manuscript.

23 0

[GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志未来预警的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了，催了几次都说会催诚信团队，但至今都卡在技术审查这步，有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肺癌 经验分享：非常快！ 27 Sep 2023 Article accepted for publication. Submitting Author re-submitted manuscript. 25 Sep 2023 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 2 is finalized. Review of Reviewer 1 is finalized. 13 Sep 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人，且这个审稿人审稿结束了，同意出版。编辑说还要邀请审稿人呢，一个审稿人不行，已经过去半个月了，还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向：头颈肿瘤;影像;Oncology 经验分享：请问我的一个个案，自我感觉头颈肿瘤和肿瘤影像两部分都可以投，我投了头颈肿瘤，但是现在已经快EA一个月了，我上面至今都没有编辑的名字（没分到编辑），我也写信推荐了（他说我可以推荐一个可能的编辑）。请问各位大佬们，如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试，不行就换杂志了，伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0 经验分享：一个月了状态还停留在Initial Validation阶段，催稿也未回复，有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向：非小细胞肺癌;临床;肿瘤免疫 经验分享：FII被拒了，能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]

2023-11-06 ms7000002110969436 来自江苏省

目前只邀请到了一个审稿人，且这个审稿人审稿结束了，同意出版。编辑说还要邀请审稿人呢，一个审稿人不行，已经过去半个月了，还没消息。

13 0

[GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志未来预警的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了，催了几次都说会催诚信团队，但至今都卡在技术审查这步，有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肺癌 经验分享：非常快！ 27 Sep 2023 Article accepted for publication. Submitting Author re-submitted manuscript. 25 Sep 2023 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 2 is finalized. Review of Reviewer 1 is finalized. 13 Sep 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人，且这个审稿人审稿结束了，同意出版。编辑说还要邀请审稿人呢，一个审稿人不行，已经过去半个月了，还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向：头颈肿瘤;影像;Oncology 经验分享：请问我的一个个案，自我感觉头颈肿瘤和肿瘤影像两部分都可以投，我投了头颈肿瘤，但是现在已经快EA一个月了，我上面至今都没有编辑的名字（没分到编辑），我也写信推荐了（他说我可以推荐一个可能的编辑）。请问各位大佬们，如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试，不行就换杂志了，伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0 经验分享：一个月了状态还停留在Initial Validation阶段，催稿也未回复，有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向：非小细胞肺癌;临床;肿瘤免疫 经验分享：FII被拒了，能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]

2023-11-01 1521ae796fm 来自四川省

有没有投稿网址啊

18 0

[GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志未来预警的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了，催了几次都说会催诚信团队，但至今都卡在技术审查这步，有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肺癌 经验分享：非常快！ 27 Sep 2023 Article accepted for publication. Submitting Author re-submitted manuscript. 25 Sep 2023 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 2 is finalized. Review of Reviewer 1 is finalized. 13 Sep 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人，且这个审稿人审稿结束了，同意出版。编辑说还要邀请审稿人呢，一个审稿人不行，已经过去半个月了，还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向：头颈肿瘤;影像;Oncology 经验分享：请问我的一个个案，自我感觉头颈肿瘤和肿瘤影像两部分都可以投，我投了头颈肿瘤，但是现在已经快EA一个月了，我上面至今都没有编辑的名字（没分到编辑），我也写信推荐了（他说我可以推荐一个可能的编辑）。请问各位大佬们，如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试，不行就换杂志了，伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0 经验分享：一个月了状态还停留在Initial Validation阶段，催稿也未回复，有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向：非小细胞肺癌;临床;肿瘤免疫 经验分享：FII被拒了，能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]

2022-05-18 ms2000001171054439

偏重的研究方向：头颈肿瘤;影像;Oncology
经验分享：请问我的一个个案，自我感觉头颈肿瘤和肿瘤影像两部分都可以投，我投了头颈肿瘤，但是现在已经快EA一个月了，我上面至今都没有编辑的名字（没分到编辑），我也写信推荐了（他说我可以推荐一个可能的编辑）。请问各位大佬们，如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试，不行就换杂志了，伤不起啊

56 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志未来预警的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了，催了几次都说会催诚信团队，但至今都卡在技术审查这步，有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肺癌 经验分享：非常快！ 27 Sep 2023 Article accepted for publication. Submitting Author re-submitted manuscript. 25 Sep 2023 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 2 is finalized. Review of Reviewer 1 is finalized. 13 Sep 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人，且这个审稿人审稿结束了，同意出版。编辑说还要邀请审稿人呢，一个审稿人不行，已经过去半个月了，还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向：头颈肿瘤;影像;Oncology 经验分享：请问我的一个个案，自我感觉头颈肿瘤和肿瘤影像两部分都可以投，我投了头颈肿瘤，但是现在已经快EA一个月了，我上面至今都没有编辑的名字（没分到编辑），我也写信推荐了（他说我可以推荐一个可能的编辑）。请问各位大佬们，如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试，不行就换杂志了，伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0 经验分享：一个月了状态还停留在Initial Validation阶段，催稿也未回复，有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向：非小细胞肺癌;临床;肿瘤免疫 经验分享：FII被拒了，能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]

2023-10-13 ms8000001912482889 来自陕西省

投稿命中率:50.0
经验分享：一个月了状态还停留在Initial Validation阶段，催稿也未回复，有没有大神解答一下什么情况啊

19 0

[GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志未来预警的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了，催了几次都说会催诚信团队，但至今都卡在技术审查这步，有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肺癌 经验分享：非常快！ 27 Sep 2023 Article accepted for publication. Submitting Author re-submitted manuscript. 25 Sep 2023 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 2 is finalized. Review of Reviewer 1 is finalized. 13 Sep 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人，且这个审稿人审稿结束了，同意出版。编辑说还要邀请审稿人呢，一个审稿人不行，已经过去半个月了，还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向：头颈肿瘤;影像;Oncology 经验分享：请问我的一个个案，自我感觉头颈肿瘤和肿瘤影像两部分都可以投，我投了头颈肿瘤，但是现在已经快EA一个月了，我上面至今都没有编辑的名字（没分到编辑），我也写信推荐了（他说我可以推荐一个可能的编辑）。请问各位大佬们，如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试，不行就换杂志了，伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0 经验分享：一个月了状态还停留在Initial Validation阶段，催稿也未回复，有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向：非小细胞肺癌;临床;肿瘤免疫 经验分享：FII被拒了，能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]

2023-10-10 P拾荒者来自浙江省

偏重的研究方向：非小细胞肺癌;临床;肿瘤免疫
经验分享：FII被拒了，能不能再投这个啊

28 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2170093, encodeId=1f9021e009306, content=偏重的研究方向：肿瘤免疫 经验分享：这个杂志未来预警的可能性大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Tue Nov 21 22:48:23 CST 2023, time=2023-11-21, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肿瘤 经验分享：非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160922, encodeId=32312160922ec, content=技术审查一个多月了，催了几次都说会催诚信团队，但至今都卡在技术审查这步，有人遇到过同样情况吗😮‍💨, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=009a8811870, createdName=ms1000000556586108, createdTime=Wed Oct 04 17:16:56 CST 2023, time=2023-10-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2167854, encodeId=4120216e85470, content=审稿速度:1.0 | 投稿命中率:95.0 偏重的研究方向：肺癌 经验分享：非常快！ 27 Sep 2023 Article accepted for publication. Submitting Author re-submitted manuscript. 25 Sep 2023 Corresponding/Submitting Author is automatically requested to revise and resubmit the manuscript. Review of Reviewer 2 is finalized. Review of Reviewer 1 is finalized. 13 Sep 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5bca6432300, createdName=ms4000000828277451, createdTime=Fri Nov 10 15:07:18 CST 2023, time=2023-11-10, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2167075, encodeId=f43d216e07557, content=目前只邀请到了一个审稿人，且这个审稿人审稿结束了，同意出版。编辑说还要邀请审稿人呢，一个审稿人不行，已经过去半个月了，还没消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1f5387570, createdName=ms7000002110969436, createdTime=Mon Nov 06 19:23:30 CST 2023, time=2023-11-06, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2166021, encodeId=fa50216602187, content=有没有投稿网址啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e201711343, createdName=1521ae796fm, createdTime=Wed Nov 01 10:20:13 CST 2023, time=2023-11-01, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1220578, encodeId=868612205e866, content=偏重的研究方向：头颈肿瘤;影像;Oncology 经验分享：请问我的一个个案，自我感觉头颈肿瘤和肿瘤影像两部分都可以投，我投了头颈肿瘤，但是现在已经快EA一个月了，我上面至今都没有编辑的名字（没分到编辑），我也写信推荐了（他说我可以推荐一个可能的编辑）。请问各位大佬们，如果我想撤稿我要写信给谁啊。我想着要不试试肿瘤影像那个部门。找个国人编辑试试，不行就换杂志了，伤不起啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87b38137467, createdName=ms2000001171054439, createdTime=Wed May 18 00:16:24 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162608, encodeId=c3d9216260818, content=投稿命中率:50.0 经验分享：一个月了状态还停留在Initial Validation阶段，催稿也未回复，有没有大神解答一下什么情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d79f8854845, createdName=ms8000001912482889, createdTime=Fri Oct 13 15:39:40 CST 2023, time=2023-10-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2161960, encodeId=16ab216196083, content=偏重的研究方向：非小细胞肺癌;临床;肿瘤免疫 经验分享：FII被拒了，能不能再投这个啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Tue Oct 10 13:34:37 CST 2023, time=2023-10-10, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2147624, encodeId=cd9a214e624c9, content=请问大家Review Finalized 阶段会多久有结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57b84693922, createdName=gaogao, createdTime=Wed Jul 12 10:55:17 CST 2023, time=2023-07-12, status=1, ipAttribution=广东省)]

2023-07-12 gaogao 来自广东省

请问大家Review Finalized 阶段会多久有结果

61 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

平台业务解决方案

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务